ADAP Share Price Performance
US$0.095
-0.90 (-90.49%)
90.1% undervalued intrinsic discount
US$0.96
Fair Value
Price US$0.095
AnalystConsensusTarget US$0.96
Fair ValueUS$0.96
Share PriceUS$0.095
90.1% undervalued intrinsic discount
ADAP Community Narratives
AN
Fair Value US$0.96 90.1% undervalued intrinsic discount
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
ADAP Community Fair Values
- US$0.96FV90.1% undervalued intrinsic discount-5.27%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative10users have followed this narrative7 days ago author updated this narrative
Recent ADAP News & Updates
No updates
Adaptimmune Therapeutics plc Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.26
- Gross Margin
- 20.03%
- Net Profit Margin
- -38.91%
- Debt/Equity Ratio
- -67.9%
Adaptimmune Therapeutics plc Competitors
About ADAP
- Founded
- 2008
- Employees
- 506
- CEO
- WebsiteView website
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
U.K. Market Performance
- 7 Days: 0.3%
- 3 Months: 18.2%
- 1 Year: 16.0%
- Year to Date: 14.9%
In the last week, the market has been flat. More promisingly, the market is up 16% over the past year. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading